Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity

Leuk Lymphoma. 2017 Apr;58(4):1002-1004. doi: 10.1080/10428194.2016.1222380. Epub 2016 Aug 26.

Authors

Jorge J Castillo¹, Joshua N Gustine¹, Kirsten Meid¹, Toni Dubeau¹, Guang Yang¹, Lian Xu¹, Zachary R Hunter¹, Steven P Treon¹

Affiliation

¹ a Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.

PMID: 27562445
DOI: 10.1080/10428194.2016.1222380

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Aged, 80 and over
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Biomarkers
Chemical and Drug Induced Liver Injury / diagnosis*
Chemical and Drug Induced Liver Injury / etiology*
Female
Humans
Liver Function Tests
Male
Middle Aged
Purines / adverse effects*
Purines / therapeutic use
Quinazolinones / adverse effects*
Quinazolinones / therapeutic use
Waldenstrom Macroglobulinemia / complications*
Waldenstrom Macroglobulinemia / drug therapy

Substances

Antineoplastic Agents
Biomarkers
Purines
Quinazolinones
idelalisib